Bayer Diagnostics
Division of Siemens Healthcare Diagnostics Inc.
www.bayerdiag.com
Latest From Bayer Diagnostics
Amersham Little Help to GE Healthcare in This Down Market
As befits this struggling economy, each of the Big Three in diagnostic imaging sounded downbeat in their 2008 year-end financial assessments. But more so than the other two, GE Healthcare focuses on the development of new imaging agents, owing to its acquisition of Amersham in late 2003. Ant that integration has been admittedly slow.
What New Her2 Tests Say about Personalized Medicine
Traditional diagnostic tests for Her2 (the target of the drug Herceptin) have well-documented failings. In July, Monogram Biosciences launched a new Her2 test, and two months later, Genomic Health added Her2 status information to its breast cancer test. They believe that more comprehensive, multianalyte tests may better guide therapy and yield a pharmacoeconomic benefit, even at eight to 10 times the cost. These developments point to the need for a more nuanced approach to the management of cancer as a chronic disease and a more nuanced view of personalized medicine.
Prostate Cancer Market: $2 Billion and Growing
Although prostate problems have plagued men for many years, the growing elderly population is now driving an unprecedented increase in caseloads and a corresponding need for improved treatments. One of the primary concerns is the rise in prostate cancer diagnoses. With more than two million American men currently living with prostate cancer and more than 200,000 new cases diagnosed each year, the market for diagnostic and therapeutic products to address this disease is substantial; more than $2 billion in the US in 2007.
In Vitro Diagnostics: Innovation and Integration
Integration is occuring at almost every level of the in vitro diagnostic industry--at the preclinical level to decrease drug development costs and timelines and at the clinical level to better manage diseases. In the lab, there's a demand for new tools to improve speed and efficiency, and new information systems to better integrate disparate data. At the same time, there has been a flurry of integration and consolidation at the market level, with 35 mergers and acquisitions in the last 12 months.
Company Information
- Industry
-
In Vitro Diagnostics
- Chemistry, Immunoassay
- Hematology, Coagulation
- Molecular Diagnostics & Genetic Testing
- Therapeutic Areas
- Non-Specific
- Alias(es)
- Bayer Diagnostics Inc.
- Ownership
- Private
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Siemens Healthcare Diagnostics Inc.
- Senior Management
-
Wolfgang Hartwig, PhD, Pres.
Javad Seyedzadeh, Head, Quality Assurance & Reg. Affairs - Contact Info
-
Bayer Diagnostics
Phone: (914) 631-8000
511 Benedict Ave.
Tarrytown, NY 10591-5097
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bayer Diagnostics
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice